Canaccord Genuity Group Reiterates “Hold” Rating for Smith & Nephew (NYSE:SNN)

Smith & Nephew (NYSE:SNN)‘s stock had its “hold” rating reaffirmed by Canaccord Genuity Group in a research note issued to investors on Monday,Benzinga reports. They presently have a $27.00 price target on the medical equipment provider’s stock. Canaccord Genuity Group’s price objective points to a potential downside of 6.44% from the stock’s current price.

Several other research analysts also recently issued reports on the company. StockNews.com upgraded Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 26th. UBS Group downgraded Smith & Nephew from a “buy” rating to a “neutral” rating in a report on Wednesday, March 12th. Four analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Smith & Nephew has a consensus rating of “Hold” and a consensus target price of $27.00.

Smith & Nephew Price Performance

Shares of Smith & Nephew stock traded up $0.29 during trading on Monday, hitting $28.86. 203,418 shares of the company were exchanged, compared to its average volume of 816,145. The company has a quick ratio of 1.11, a current ratio of 2.51 and a debt-to-equity ratio of 0.63. Smith & Nephew has a fifty-two week low of $23.65 and a fifty-two week high of $31.72. The stock has a market capitalization of $12.62 billion, a price-to-earnings ratio of 13.36, a P/E/G ratio of 1.26 and a beta of 0.83. The firm has a 50 day moving average price of $26.35 and a 200 day moving average price of $27.12.

Institutional Trading of Smith & Nephew

A number of institutional investors and hedge funds have recently made changes to their positions in the company. River Road Asset Management LLC increased its holdings in shares of Smith & Nephew by 64.0% during the 4th quarter. River Road Asset Management LLC now owns 2,032,016 shares of the medical equipment provider’s stock worth $49,947,000 after buying an additional 792,829 shares during the last quarter. J. Goldman & Co LP acquired a new stake in shares of Smith & Nephew during the 4th quarter worth $47,700,000. Brandes Investment Partners LP increased its holdings in shares of Smith & Nephew by 11.4% during the 4th quarter. Brandes Investment Partners LP now owns 1,363,039 shares of the medical equipment provider’s stock worth $33,504,000 after buying an additional 138,994 shares during the last quarter. Clark Estates Inc. NY boosted its position in Smith & Nephew by 16.8% during the 4th quarter. Clark Estates Inc. NY now owns 800,000 shares of the medical equipment provider’s stock worth $19,664,000 after purchasing an additional 115,000 shares during the period. Finally, Envestnet Asset Management Inc. boosted its position in Smith & Nephew by 11.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 535,350 shares of the medical equipment provider’s stock worth $13,159,000 after purchasing an additional 57,014 shares during the period. 25.64% of the stock is currently owned by institutional investors and hedge funds.

About Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.